Trends in mortality from infection among patients with hematologic malignancies: differences according to hematologic malignancy subtype.

IF 3.3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Xuejiao Yin, Xuelian Hu, Hongyan Tong, Liangshun You
{"title":"Trends in mortality from infection among patients with hematologic malignancies: differences according to hematologic malignancy subtype.","authors":"Xuejiao Yin,&nbsp;Xuelian Hu,&nbsp;Hongyan Tong,&nbsp;Liangshun You","doi":"10.1177/20406223231173891","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Infection is the most important cause of non-relapse mortality in hematologic malignancy patients, leading to increased costs and prolonged hospitalization times. However, comprehensive and comparable reports on infection-specific mortality (ISM) trends in hematologic malignancy patients are lacking.</p><p><strong>Objectives: </strong>We aimed to provide updated ISM trends and factors associated with ISM among hematologic malignancy patients.</p><p><strong>Design: </strong>This is a retrospective study.</p><p><strong>Methods: </strong>Patients diagnosed with the five most common hematologic malignancies from 1983 to 2016 from the Surveillance, Epidemiology, and End Results database were included. Joinpoint regression was used to analyze mortality trends.</p><p><strong>Results: </strong>ISM decreased beginning in 1983, 1988, and 1994, with yearly decreases of -2.1% for acute leukemia (AL), -1.3% for Hodgkin lymphoma (HL), and -14.3% for non-Hodgkin lymphoma (NHL). In contrast, ISM in patients with chronic leukemia (CL) and multiple myeloma (MM) increased dramatically beginning in 2000, with yearly increases of 2.8% and 3.3%, respectively. ISM rates were higher in males than in females across all hematologic malignancy subtypes. The mortality trends significantly differed according to race, age, sex, and stage, which could help in further etiological investigations. Moreover, male sex, older age at diagnosis, black race, and unmarried status were poor prognostic factors for ISM across all hematologic malignancy subtypes.</p><p><strong>Conclusion: </strong>A promising downward trend in ISM in recent years occurred in patients with AL, HL, and NHL; however, ISM increased dramatically in patients with CL and MM. Our data suggest that risk assessment and careful infection monitoring are recommended for hematologic malignancy patients, particularly those with CL and MM.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"14 ","pages":"20406223231173891"},"PeriodicalIF":3.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/36/10.1177_20406223231173891.PMC10288445.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Chronic Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406223231173891","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Infection is the most important cause of non-relapse mortality in hematologic malignancy patients, leading to increased costs and prolonged hospitalization times. However, comprehensive and comparable reports on infection-specific mortality (ISM) trends in hematologic malignancy patients are lacking.

Objectives: We aimed to provide updated ISM trends and factors associated with ISM among hematologic malignancy patients.

Design: This is a retrospective study.

Methods: Patients diagnosed with the five most common hematologic malignancies from 1983 to 2016 from the Surveillance, Epidemiology, and End Results database were included. Joinpoint regression was used to analyze mortality trends.

Results: ISM decreased beginning in 1983, 1988, and 1994, with yearly decreases of -2.1% for acute leukemia (AL), -1.3% for Hodgkin lymphoma (HL), and -14.3% for non-Hodgkin lymphoma (NHL). In contrast, ISM in patients with chronic leukemia (CL) and multiple myeloma (MM) increased dramatically beginning in 2000, with yearly increases of 2.8% and 3.3%, respectively. ISM rates were higher in males than in females across all hematologic malignancy subtypes. The mortality trends significantly differed according to race, age, sex, and stage, which could help in further etiological investigations. Moreover, male sex, older age at diagnosis, black race, and unmarried status were poor prognostic factors for ISM across all hematologic malignancy subtypes.

Conclusion: A promising downward trend in ISM in recent years occurred in patients with AL, HL, and NHL; however, ISM increased dramatically in patients with CL and MM. Our data suggest that risk assessment and careful infection monitoring are recommended for hematologic malignancy patients, particularly those with CL and MM.

Abstract Image

Abstract Image

Abstract Image

恶性血液病患者感染死亡率趋势:不同恶性血液病亚型的差异
背景:感染是恶性血液病患者非复发性死亡的最重要原因,导致费用增加和住院时间延长。然而,关于恶性血液病患者感染特异性死亡率(ISM)趋势的综合和可比较的报告是缺乏的。目的:我们旨在提供血液恶性肿瘤患者ISM的最新趋势和相关因素。设计:这是一项回顾性研究。方法:从监测、流行病学和最终结果数据库中纳入1983 - 2016年诊断为5种最常见血液恶性肿瘤的患者。采用结合点回归分析死亡率趋势。结果:ISM从1983年、1988年和1994年开始下降,急性白血病(AL)年下降2.1%,霍奇金淋巴瘤(HL)年下降1.3%,非霍奇金淋巴瘤(NHL)年下降14.3%。相比之下,慢性白血病(CL)和多发性骨髓瘤(MM)患者的ISM从2000年开始急剧增加,年增长率分别为2.8%和3.3%。在所有血液恶性肿瘤亚型中,男性的ISM发病率高于女性。死亡率趋势因种族、年龄、性别和分期而有显著差异,这有助于进一步的病因调查。此外,男性、诊断时年龄较大、黑人种族和未婚状态是所有血液恶性肿瘤亚型中ISM的不良预后因素。结论:近年来,AL、HL和NHL患者的ISM呈下降趋势;然而,ISM在CL和MM患者中显著增加。我们的数据表明,对于血液恶性肿瘤患者,特别是CL和MM患者,建议进行风险评估和仔细的感染监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Chronic Disease
Therapeutic Advances in Chronic Disease Medicine-Medicine (miscellaneous)
CiteScore
6.20
自引率
0.00%
发文量
108
审稿时长
12 weeks
期刊介绍: Therapeutic Advances in Chronic Disease publishes the highest quality peer-reviewed research, reviews and scholarly comment in the drug treatment of all chronic diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers involved in the medical treatment of chronic disease, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信